Sly Saint
Senior Member (Voting Rights)
Treating chronic fatigue syndrome, also known as myalgic encephalomyelitis (CFS/ME), starts with getting the right diagnosis – something that, for many patients, can prove elusive. Characterised by debilitating tiredness, the condition is notoriously difficult to pin down and even more challenging to treat.
CFS/ME expands far beyond exhaustion alone, with patients often also enduring flulike symptoms, musculoskeletal pain and brain fog. Around one in four people with CFS/ME are so severely unwell they are housebound.
The difficulties in obtaining a diagnosis are numerous. Patients typically undergo extensive tests for their various physical symptoms before landing on a diagnosis of CFS/ME when no other condition can be found to fit.
Symptoms can be nebulous and vary over time, leading to uncertainty about the underlying problem for both the patient and clinician and many people with CFS/ME also report being repeatedly disbelieved by doctors.
The emergence of long Covid – which some clinicians believe could be CFS/ME presenting at a large scale from one single, identifiable cause – has reopened the discussion around ME diagnosis.
Research carried out at Imperial College London recently suggested that long Covid could be diagnosed through a simple blood test. Researchers have been able to find specific autoantibodies in the blood of long Covid patients that were not found in the blood of people who recovered quickly from Covid-19 or never tested positive for the disease.
Where regular antibodies work to fight off infections, autoantibodies mistakenly target and react with a person’s own tissue and organs, rather than invading pathogens.
But while long Covid may well be a subsection of CFS/ME, the condition at large is likely to be a multisystem, multifactorial disease – not every case will have been triggered by one specific viral infection. This means that any objective diagnostic test for CFS/ME will need to be far more complex than a standalone blood test.
Post-exertional malaise and microRNA
There is no objective test for CFS/ME yet, but there have been steps in the right direction.
A key marker of CFS/ME is post-exertional malaise (PEM), the worsening of symptoms within 12 to 48 hours of even minor physical or mental exertion, that can then last for days or weeks. This symptom was utilised by researchers attempting to develop a molecular test for the disease in a November 2020 study published in Scientific Reports.
rest of article here
https://www.medicaldevice-network.com/features/cfs-me-test/